The Manufacturers Life Insurance Company Sells 3,078 Shares of Insulet Corporation $PODD

The Manufacturers Life Insurance Company lowered its stake in shares of Insulet Corporation (NASDAQ:PODD) by 7.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,619 shares of the medical instruments supplier’s stock after selling 3,078 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.05% of Insulet worth $7,684,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. State Street Corp raised its stake in Insulet by 2.1% during the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock worth $896,916,000 after buying an additional 65,317 shares during the period. Geode Capital Management LLC increased its holdings in shares of Insulet by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock worth $568,274,000 after acquiring an additional 41,019 shares in the last quarter. Invesco Ltd. raised its position in shares of Insulet by 10.5% during the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock worth $420,835,000 after purchasing an additional 141,167 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Insulet by 462.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after purchasing an additional 1,011,369 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Insulet during the 4th quarter valued at about $300,794,000.

Insider Buying and Selling at Insulet

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.36% of the company’s stock.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Neutral Sentiment: Insulet is scheduled to report second-quarter 2026 results shortly, making the upcoming earnings release a key near-term catalyst. Investors will likely focus on Omnipod product quality, manufacturing remediation, demand, and management’s outlook. Insulet Q2 2026 Earnings Preview
• Negative Sentiment: A federal securities class action was filed against Insulet and certain officers on behalf of investors who purchased securities during periods ranging from February 21 or May 21, 2025, through May 26, 2026. The allegations center on potentially misleading statements about Omnipod manufacturing quality and product safety; the claims have not been proven in court. Investors have until August 31, 2026, to seek appointment as lead plaintiff. Pomerantz class-action announcement
• Negative Sentiment: Investor-law-firm notices link the lawsuit to two Omnipod medical-device corrections and allege that the issues revealed broader quality-control problems, contributing to a decline of more than 6% in the stock and a reported roughly $90-per-share loss from prior optimism. The growing number of legal solicitations increases reputational, financial, and litigation risks for Insulet. Insulet stock-drop and class-action notice

Insulet Stock Performance

NASDAQ:PODD opened at $166.82 on Wednesday. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $11.55 billion, a PE ratio of 38.80, a price-to-earnings-growth ratio of 1.18 and a beta of 1.10. Insulet Corporation has a twelve month low of $138.79 and a twelve month high of $354.88. The stock’s 50-day simple moving average is $155.82 and its 200 day simple moving average is $196.09.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same period in the previous year, the firm posted $1.02 EPS. The firm’s revenue was up 33.9% on a year-over-year basis. On average, analysts anticipate that Insulet Corporation will post 6.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PODD. Weiss Ratings downgraded shares of Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, June 24th. William Blair initiated coverage on Insulet in a research report on Wednesday, May 20th. They set an “outperform” rating for the company. Oppenheimer reduced their target price on Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Royal Bank Of Canada decreased their target price on Insulet from $280.00 to $245.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Finally, Jefferies Financial Group cut their price target on Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Twenty-one investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $233.38.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.